The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Matthew S. Davids | iwCLL 2017 | Ibrutinib + FCR or duvelisib + FCR in the front line setting for high-risk CLL patients

May 18, 2017

Ibrutinib + FCR or duvelisib + FCR in the front line setting for high-risk CLL patients